



## Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference

February 21, 2025

CONSHOHOCKEN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the 45th Annual TD Cowen Health Care Conference on Tuesday, March 4, 2025 at 11:10 A.M. ET.

The presentation will be webcast live and may be accessed [here](#) or by visiting Madrigal's Investor Relations Events [page](#). A replay of the webcast will be available after the event.

### About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR- $\beta$  agonist designed to target key underlying causes of MASH. For more information, visit [www.madrigalpharma.com](http://www.madrigalpharma.com).

### Investor Contact

Tina Ventura, [IR@madrigalpharma.com](mailto:IR@madrigalpharma.com)

### Media Contact

Christopher Frates, [media@madrigalpharma.com](mailto:media@madrigalpharma.com)



Source: Madrigal Pharmaceuticals, Inc.